

BENITEC LIMITED

8 January 2008

ASX Limited
Att: Marta Kielich
20 Bridge Street
Sydney NSW 2000

ABN 64 068 943 662

Registered Office
Level 16, 356 Collins St
Melbourne VIC 3000
Australia

Head Office
Level 1, 123 Camberwell Rd
Hawthorn East Vic 3123
Australia

Dear Ms Kielich

Ph: +61 3 98119974
Fax: +61 3 98131201

www.benitec.com

REPLY TO FURTHER QUERY

I refer to your letter dated 8 January 2008 which noted the following:


- The ASX price query letter dated 2 January 2008;
- The response from Benitec (“the Company”) dated 3 January 2008; and
- The Company’s announcement on 8 January 2008.

We respond to your questions as follows:

1. Benitec considers the information contained in the Announcement to be material to the Company.
2. Not applicable.
3. The Company was first informed this morning by Tacere Therapeutics, Inc., our licensee, that they had completed an agreement with Pfizer Inc. Benitec was not a party to any of the discussions or negotiations between Tacere and Pfizer nor were we informed of their progress.
4. Following notification this morning by our licensee that an Agreement had been completed, Benitec immediately requested a trading halt prior to the open of the market, pending an announcement to the market.
5. Benitec was aware that Tacere was in discussions with a number of third parties including Pfizer. This is common practice for a company in the biotechnology sector. However the Company had no knowledge that any agreement was being negotiated or nearing completion.
6. As the Company had no knowledge of the negotiations between the parties, we are unable to comment upon whether the increase in the share price before the Announcement indicated that confidentiality in relation to the Agreement had been lost.
7. We confirm that the Company continues to be in compliance with the Listing Rules and, in particular, Listing Rule 3.1.

Please call me if you have any queries in respect of the above.

Yours faithfully



John Rawling
Company Secretary